课题基金 / 基金详情

COMBINED ERYTHROPOIETIN/HYDROXYUREA THERAPY FOR SICKLE CELL ANEMIA

COMBINED ERYTHROPOIETIN/HYDROXYUREA THERAPY FOR SICKLE CELL ANEMIA
促红细胞生成素/羟基脲联合治疗镰状细胞性贫血
批准号:
3787248
负责人:
SAMUEL CHARACHE
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

SAMUEL CHARACHE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Administration of hydroxyurea to patients with Sickle Cell Anemia causes increased Hb F production in some, but not all, patients. There is no accepted explanation for the phenomenon, but one which has been suggested is that the drug kills late red cell precursors and causes recruitment of earlier forms with an intrinsically higher program for Hb F synthesis. We have data which dispute this hypothesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMBINED ERYTHROPOITIN/HYDROXYUREA THERAPY FOR SICKLE CELL ANEMIA
  • 批准号:
    3886769
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    SAMUEL CHARACHE
  • 依托单位:
TREATMENT OF SICKLE CELL DISEASE WITH 5-AZA-CYTIDINE
  • 批准号:
    4697970
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    SAMUEL CHARACHE
  • 依托单位:
NATURAL HISTORY OF SICKLE CELL ANEMIA
  • 批准号:
    4697955
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    SAMUEL CHARACHE
  • 依托单位:
ERYTHROPOEITIN/HYDROXYUREA IN SICKLE CELL ANEMIA
  • 批准号:
    3882816
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    SAMUEL CHARACHE
  • 依托单位:
海外基金